Ethical Dilemmas and Responsibility of Regulators During a Pandemic
Monday, June 15, 2020
12pm EDT / 7pm Israel / 6pm France
How do we approach expediting the regulatory process while ensuring safety in times of a pandemic. Four incredible regulatory experts will discuss topics importance speed vs safety, sharing of data, importance of open label and real world evidence in times of crisis, supply restrictions due to demand over supply, and much more.
Principal Deputy Commissioner, Immediate Office of the Commissioner, U.S. Food and Drug Administration
Former Assistant to the President, Director of the Domestic Policy Council, The White House
Murray "Mac" Lumpkin
Deputy Director, Integrated Development (Lead for Global Regulatory Systems Initiatives), Bill & Melinda Gates Foundation; Prior Director of the Anti-Infective Drug Division; Prior Deputy Director of CDER and Former Deputy Commissioner of the International Programs of the FDA
Andrew C. von Eschenbach
Previous Commissioner of Department of Health and Human Services and Director of the National Cancer Institute
In the last few months, sweeping regulation and policy changes are reshaping health care, from medical research to clinical trials to CMS reimbursement. On June 15th, join a panel of global thought-leaders will examine the shift in the regulatory paradigm and the ethical considerations around finding treatments for patients.